ESMO 2022 Conference Coverage
Lecture Summary - ESMO 2022 on Primary Endpoint Results of the Randomized Phase 2 SYNERGY Trial: 1L Chemo-IO of Durvalumab, Paclitaxel, and Carboplatin +/- Anti-CD73 Antibody Oleclumab in Advanced or Metastatic TNBC
By
ESMO 2022 Conference Coverage
FEATURING
Laurence Buisseret
By
ESMO 2022 Conference Coverage
FEATURING
Laurence Buisseret
Login to view comments.
Click here to Login
Breast